Taken together, these data suggest that inhibition of ZSCAN21 SUMOylation may favour PD by impairing the ZSCAN21/TRIM41 interaction, thereby promoting ZSCAN21 accumulation and increasing α-synuclein protein levels. Here, ZSCAN21 is linked to Parkinson disease.